【华东医药：控股子公司注射用DR30206临床试验获批】华东医药公告称，公司控股子公司浙江道尔生物科技有限公司收到国家药监局核准签发的《药物临床试验批准通知书》，其申报的注射用DR30206临床试验申请获得批准，该药品为1类治疗用生物制品，本次获批适应症为联合标准化疗拟用于治疗复发或转移性头颈部鳞状细胞癌患者。注射用DR30206是道尔生物自主研发并拥有全球知识产权的靶向PD-L1、VEGF和TGF-β的抗体融合蛋白，本次获批是该款新药研发进程中的重要进展，对公司近期业绩不会产生重大影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.